loader from loading.io

How Has Antithrombotic Therapy for PAD Changed Over the Last Decade?

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Release Date: 11/12/2024

ACCEL Lite: Should There Be a Reappraisal of Surgical Threshold in Patients with AA Dilation?    show art ACCEL Lite: Should There Be a Reappraisal of Surgical Threshold in Patients with AA Dilation?

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Ascending aortopathy (AA) is typically asymptomatic and often diagnosed incidentally, with surgical aortic replacement recommended once aneurysmal thresholds are reached. Emerging evidence suggests that indexing aortic size to patient height may more accurately identify individuals who could benefit from earlier intervention. For AA patients who do not currently meet guideline-based criteria for surgery, the aim is to assess how height-indexed aortic measurements influence longer‑term clinical outcomes in this population.    In this interview, Glenn...

info_outline
Top Takeaways from 2025: Preventive Cardiology with C. Noel Bairey Merz, MD, MACC show art Top Takeaways from 2025: Preventive Cardiology with C. Noel Bairey Merz, MD, MACC

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

In this interview, C. Noel Bairey Merz MD, MACC and Alison L. Bailey, MD FACC, discuss the Top Preventive Cardiology Takeaways from 2025 including trials clopidogrel versus aspirin, the benefit of vaccines, statin use in pregnancy, and more.  Suggested Materials:   Valgimigli M, Choi KH, Giacoppo D, et al. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis. Lancet. 2025;406(10508):1091-1102. doi:10.1016/S0140-6736(25)01562-4  O’Leary K. Influenza vaccination...

info_outline
Top Takeaways from 2025: EP with DJ Lakkireddy, MBBS, FACC show art Top Takeaways from 2025: EP with DJ Lakkireddy, MBBS, FACC

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

In this interview, DJ Lakkireddy, MBBS, FACC and Alison L. Bailey, MD FACC, discuss the Top Electrophysiology Takeaways from 2025 including trials CLOSURE-AF, ALONE-AF, NEMESIS-PFA, and more.   Suggested Materials:  1. Verma A, Birnie DH, Jiang C, et al. Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. N Engl J Med. Published online November 8, 2025. doi:10.1056/NEJMoa2509688    2. Landmesser U, Skurk C, Kirchhof P, et al. Catheter-based left atrial appendage CLOSURE in patients with atrial fibrillation...

info_outline
Multimodality Imaging in Inflammatory Cardiomyopathy show art Multimodality Imaging in Inflammatory Cardiomyopathy

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Multimodality imaging plays a pivotal role in evaluating inflammatory cardiomyopathy, particularly when cardiac sarcoidosis (CS) is suspected. Symptoms of CS include unexplained high-grade AV block, ventricular arrhythmias, reduced left ventricular function, or regional wall thinning without coronary disease. The best evaluation combines cardiac magnetic resonance imaging (MRI) for structural and scar assessment with fluorodeoxyglucose (FDG)-positron emission tomography (PET) for detecting active inflammation and extracardiac involvement.    In...

info_outline
Top Takeaways from 2025: Clinical Cardiology with Allen J. Taylor, MD, FACC show art Top Takeaways from 2025: Clinical Cardiology with Allen J. Taylor, MD, FACC

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

In this interview, Allen J. Taylor, MD, FACC and Alison L. Bailey, MD FACC, discuss the Top Clinical Cardiology Takeaways from 2025 including trials SCOT-HEART 2, ALONE-AF, Launch-HTN, and more.     Suggested Materials:  1. Kim D, Shim J, Choi EK, et al. Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial. JAMA. 2025;334(14):1246-1254. doi:10.1001/jama.2025.14679   2. Lemesle G, Didier R, Steg PG, et al. Aspirin in Patients with Chronic Coronary Syndrome Receiving...

info_outline
Top Takeaways from 2025: Interventional Cardiology with Deepak Bhatt, MD, MPH, MBA, FACC show art Top Takeaways from 2025: Interventional Cardiology with Deepak Bhatt, MD, MPH, MBA, FACC

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

In this interview, Deepak Bhatt, MD, MPH, FACC and Alison L. Bailey, MD FACC, discuss the Top Interventional Cardiology Takeaways from 2025 including DanGer Shock trial, revascularization in STEMI, aspirin withdrawal after PCI, and more.     Suggested Materials:  1. Møller JE, Beske RP, Engstrøm T, et al. Long-Term Outcomes of the DanGer Shock Trial. N Engl J Med. 2025;393(10):1037-1038. doi:10.1056/NEJMc2508284      2. Ueyama HA, Akita K, Kiyohara Y, et al. Optimal Strategy for Complete...

info_outline
PANTHER-P2Y12 Inhibitor or Aspirin moNoTHERapy as Secondary Prevention in Patients with CAD show art PANTHER-P2Y12 Inhibitor or Aspirin moNoTHERapy as Secondary Prevention in Patients with CAD

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

he PANTHER study indicates that clopidogrel provides superior protection against major cardiovascular events compared to aspirin in patients with coronary artery disease, without increasing bleeding risk. This supports its use in individuals at higher risk of gastrointestinal complications, reinforcing current clinical preferences. Overall, these results could inform long-term treatment strategies and improve outcomes for millions of patients worldwide.    In this interview, Alison L. Bailey, MD, FACC and Prof. Marco Valgimigli discuss “PANTHER-P2Y12...

info_outline
ACCEL Lite: Top Takeaways from 2025: HF with Clyde Yancy MD, MSc, MACC show art ACCEL Lite: Top Takeaways from 2025: HF with Clyde Yancy MD, MSc, MACC

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

In this interview, Clyde Yancy MD, MSc, MACC and Alison L. Bailey, MD FACC, discuss the Top Heart Failure Takeaways from 2025 including trials SUMMIT and BaxHTN, the ACC/AHA Blood Pressure Guidelines, and more.  Suggested Materials:  1. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am...

info_outline
ACCEL Lite: Top Takeaways from 2025: CV Imaging with Amit R. Patel, MD, FACC show art ACCEL Lite: Top Takeaways from 2025: CV Imaging with Amit R. Patel, MD, FACC

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

In this interview, Amit R. Patel, MD, FACC and Alison L. Bailey, MD FACC, discuss the Top Cardiovascular Imaging Takeaways from 2025 including myocardial fibroblast activation, photon-counting detector CT, the newly published ACC/AHA CT Advanced Training Statement, and more.  Suggested Materials:  1. Nijveldt R, Maeng M, Beijnink CWH, et al. Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction. N Engl J Med. Published online October 28, 2025. doi:10.1056/NEJMoa2512918      2. Barton AK, Craig NJ, Loganath K, et...

info_outline
C-Reactive Protein and CV Risk in the General Population show art C-Reactive Protein and CV Risk in the General Population

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Inflammation is a key contributor to cardiovascular disease (CVD), influencing both its onset and progression. High-sensitivity C-reactive protein (hsCRP) serves as a reliable biomarker for detecting systemic inflammation and assessing cardiovascular risk. Recognizing the role of inflammation helps refine risk stratification and guide preventive strategies in the general population.    In this interview, Nanette Kass Wenger MD, MACC and Prof. Dr. Florian Kahles, MD discuss “C-Reactive Protein and CV Risk in the General Population”.   SUGGESTED MATERIALS:  ...

info_outline
 
More Episodes

Medical therapy is critical in preventing the worst complications of peripheral artery disease (PAD), among them heart attack, stroke, bleeding risk, and leg disease, which could lead to acute limb ischemia and amputation. Blood thinning medications (antithrombotic therapy) have shown rapid evolution and broad benefits and novel approved strategies that improve outcomes are available. It is imperative that clinicians select appropriate patients for use and consider the complex situations for management. 

In this interview, Drs. Cindy Grines and Marc Bonaca discuss Antithrombotic Strategies for Patients with Peripheral Artery Disease: JACC Scientific Statement.